Trial Profile

Multicentre randomised trial of chlorambucil versus chlorambucil plus rituximab versus rituximab alone in extranodal marginal zone bcell lymphoma of mucosa associated lymphoid tissue (malt lymphoma)

Status: Completed

Phase of Trial: Phase III

Latest Information Update: 12 Oct 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Chlorambucil (Primary) ; Rituximab (Primary)
Indications Marginal zone B-cell lymphoma
Focus Therapeutic Use

Most Recent Events

06 Oct 2023 Results (n=401) assessing Early Complete Response as Validated Surrogate Marker in Extranodal Marginal Zone Lymphoma Systemic Therapy published in the Blood
18 Jul 2017 Results of a MALT lymphoma prognostic index generated using data from 401 patients enrolled in this trial, published in the Blood.
29 Mar 2017 Results published in the Journal of Clinical Oncology

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com